Let’s dig into the relative performance of Bio-Techne (NASDAQ:TECH) and its peers as we unravel the now-completed Q4 research ...

Shares of Bio-Techne Corp. TECH shed 2.04% to $58.73 Friday, on what proved to be an all-around poor trading session for the ...

Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe, Middle East and Africa (EMEA) region ...

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are covering the firm, Marketbeat.com reports. Four ...

Corporation announced further advancements in its ongoing strategy to bring translational discoveries to patient care by ...

Proficio Capital Partners LLC increased its position in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 13.6% in the 4th quarter, according to its most recent disclosure with the SEC. The ...

Argus analyst David Toung lowered the firm’s price target on Bio-Techne (TECH) to $90 from $95 and keeps a Buy rating on the shares after its ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Based in Minneapolis, Bio-Techne develops and markets protein-based instruments and reagents for research and clinical use. Its customers include companies in the pharmaceutical and biotech ...

Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed ...

This was the stock's second consecutive day of losses.